PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.

Abstract:

INTRODUCTION:Gut-specific homing is mainly mediated by the expression of MAdCAM-1 on endothelial cells. An increase in MAdCAM-1 expression has been shown in patients with inflammatory bowel disease (IBD). Areas covered: PF-00547659 is a fully human monoclonal antibody (mAb) toward MAdCAM-1 on endothelial cells, blocking its binding with the α4β7 integrin on leukocytes. This review discusses the available data on effectiveness and safety of PF-00547659 in IBD. Expert opinion: A phase II study in moderate-to-severe ulcerative colitis (UC) patients, both naïve and previously exposed to anti-tumor necrosis factors, showed that PF-00547659 was superior to placebo for induction of remission, response, and mucosal healing at week 12. In contrast, preliminary results in a similar study in Crohn's disease (CD) did not show a superiority of PF-00547659, suggesting that PF-00547659 may have limited impact over CD outcomes. However, the time frame needed to evaluate clinical effectiveness of PF-00547659 may be longer in CD patients, given its transmural characteristic. In addition, it should be taken into consideration the possibility of incorporating new tools and more objective parameters in disease assessment that are proven to better correlate with inflammation. Future randomized-controlled trials are needed to confirm the efficacy of PF-00547659 in CD.

authors

Allocca M,Gilardi D,Fiorino G,Furfaro F,Argollo M,Peyrin-Biroulet L,Danese S

doi

10.1080/13543784.2018.1494722

subject

Has Abstract

pub_date

2018-07-01 00:00:00

pages

623-629

issue

7

eissn

1354-3784

issn

1744-7658

journal_volume

27

pub_type

杂志文章,评审
  • Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.

    abstract::Heat shock proteins are vital to cell survival under conditions of stress. They bind client proteins to assist in protein stabilization, translocation of polypeptides across cell membranes and recovery of proteins from aggregates. Heat shock protein inhibitors are a diverse group of novel agents that have been demonst...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903158934

    authors: Hanson BE,Vesole DH

    更新日期:2009-09-01 00:00:00

  • American Association for Cancer Research: Clinical trials of immunotherapeutics and immunologic monitoring. April 1-5, 2000, San Francisco, CA, USA.

    abstract::A major session at this annual gathering of the cancer researchers from around the globe dealt with the current state of immunotherapy for cancer. Immunotherapy is a form of cancer treatment that enhances its scientific promise and legitimacy with each passing year. As a result, this topic has become one of the most h...

    journal_title:Expert opinion on investigational drugs

    pub_type:

    doi:10.1517/13543784.9.6.1413

    authors: Salgaller ML

    更新日期:2000-06-01 00:00:00

  • Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy.

    abstract::PDE3 cyclic nucleotide phosphodiesterases are important in cyclic AMP (cAMP) and possibly cyclic GMP-mediated signalling in cardiac and vascular smooth muscle myocytes. Drugs that inhibit these enzymes have inotropic and vasodilatory actions that have proven useful in the short-term treatment of contractile failure an...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.11.1529

    authors: Movsesian MA,Alharethi R

    更新日期:2002-11-01 00:00:00

  • Novel medications for asthma: a look at the future.

    abstract::The principal components of the asthmatic response are airways hyper-responsiveness, persistent inflammation and mucus hypersecretion. Although these components are inter-related, any of these can predominate at different times and for different patients and each requires a different approach to therapy. As a result o...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.6.889

    authors: Rubin BK,Fink JB

    更新日期:2007-06-01 00:00:00

  • Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.

    abstract:INTRODUCTION:Fibroblast growth factor receptors (FGFR 1-4) are a highly conserved family of receptor tyrosine kinases, involved in several physiological processes. Genetic aberrations of FGFRs and their ligands, fibroblast growth factors (FGFs) are involved in several pathological processes including cancer. The FGF-FG...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2020.1838484

    authors: Chandana SR,Babiker HM,Mahadevan D

    更新日期:2020-12-01 00:00:00

  • Investigational MET inhibitors to treat Renal cell carcinoma.

    abstract::Introduction: Renal cell carcinoma (RCC) consists of distinct clinical and biologic entities, with an urgent need for novel therapies targeting histology-specific molecular drivers of cancer growth. The MET pathway is now being targeted by multiple novel agents in clinical development. This review highlights the upcom...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2019.1673366

    authors: Nandagopal L,Sonpavde GP,Agarwal N

    更新日期:2019-10-01 00:00:00

  • Is everolimus useful in preventing allograft rejection and vasculopathy after heart transplant?

    abstract::The main cause of illness and death after the first year of heart transplantation is vasculopathy of the cardiac allograft, probably initiated by early immunological and non-immunological endothelial damage. The incidence of multiple episodes of grade 3A rejection 6 months after primary heart transplantation was lower...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.13.2.161

    authors: Doggrell SA

    更新日期:2004-02-01 00:00:00

  • COX-2 inhibitors as adjunctive therapy in schizophrenia.

    abstract::Cyclooxygenase-2 (COX-2) is constitutively expressed in the central nervous system, and is thought to have an important functional role therein. COX-2 interacts with neurotransmitters such as acetylcholine, 5-hydroxytryptamine and glutamate but is also involved in the regulation of the central nervous system immune sy...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.8.1033

    authors: Müller N,Strassnig M,Schwarz MJ,Ulmschneider M,Riedel M

    更新日期:2004-08-01 00:00:00

  • Dronedarone: an amiodarone analogue.

    abstract::Of the antiarrhythmic drugs in current use, amiodarone is one of the most effective and is associated with a comparatively low risk of drug-induced pro-arrhythmia, probably due to its multiple pharmacological actions on cardiac ion channels and receptors. However, amiodarone is associated with significant extra-cardia...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.4.415

    authors: Doggrell SA,Hancox JC

    更新日期:2004-04-01 00:00:00

  • Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies.

    abstract:INTRODUCTION:Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations in the dystrophin (DMD) gene. Most patients die from respiratory failure or cardiomyopathy. There are significant unmet needs for treatments for DMD as the standard of care is principally limited to symptom relief throu...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2021.1868434

    authors: Sheikh O,Yokota T

    更新日期:2021-01-06 00:00:00

  • New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca2+ channel blocker.

    abstract::Intravenous antihypertensive agents are used in clinical situations in which the immediate, precise control of blood pressure is a clinical necessity. Clevidipine is a new, vascular-selective, dihyrdopyridine Ca(2+) channel blocker, which exerts its hemodynamic effects through selective arterial vasodilation without e...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.9.1449

    authors: Gradman AH,Vivas Y

    更新日期:2007-09-01 00:00:00

  • Sorafenib in locally advanced or metastatic breast cancer.

    abstract:INTRODUCTION:Sorafenib is an oral multikinase inhibitor with anti-angiogenic and anti-proliferative activity that is indicated for use in hepatocellular and renal cell carcinomas. Sorafenib is being developed in a number of solid tumors, including breast cancer (BC). AREAS COVERED:A series of four randomized, double-b...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.689824

    authors: Gradishar WJ

    更新日期:2012-08-01 00:00:00

  • Delafloxacin for the treatment of respiratory and skin infections.

    abstract:INTRODUCTION:There has been a striking increase in the emergence of multidrug-resistant pathogens in recent times. Delafloxacin is a novel, broad-spectrum fluoroquinolone with antimicrobial activity against resistant Gram-positive, Gram-negative and anaerobic organisms. It has the potential to treat a variety of infect...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2015.1005205

    authors: Bassetti M,Della Siega P,Pecori D,Scarparo C,Righi E

    更新日期:2015-03-01 00:00:00

  • Use of botulinum toxins in cancer therapy.

    abstract::A recent study has demonstrated for the first time that botulinum neurotoxin (BoNT) briefly opens tumour vessels, allowing more effective destruction of cancer cells by radiotherapy and chemotherapy. This review discusses the implications of BoNTs in cancer treatment. After briefly reviewing the different BoNT serotyp...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.2.209

    authors: Ansiaux R,Gallez B

    更新日期:2007-02-01 00:00:00

  • The prospects of hepatic drug delivery and gene therapy.

    abstract::Liver targeted therapy is designed to deliver a substance preferentially to the organ in order to increase the accumulation, improve the therapeutic effect and reduce toxicity to other organs. The aim of selective targeting is to deliver a substance to a specific cell type in the liver. A variety of vehicles have been...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.11.1795

    authors: Wu J,Wu GY,Zern MA

    更新日期:1998-11-01 00:00:00

  • Vascular-disrupting agents in oncology.

    abstract:INTRODUCTION:Vascular-disrupting agents (VDAs) are a new class of oncology drugs, which specifically target established tumor neovasculature and have a relatively low toxicity profile. VDAs generally have non-overlapping side effects when concomitantly used with conventional cytotoxics. Several members of the VDA class...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2013.759557

    authors: Mita MM,Sargsyan L,Mita AC,Spear M

    更新日期:2013-03-01 00:00:00

  • Recent advances in the management of adult myositis.

    abstract::Standard drug therapy of adult polymyositis, dermatomyositis and inclusion body myositis includes high-dose corticosteroids and cytotoxic drugs (methotrexate, azathioprine (AZA) and cyclophosphamide). Recent data are in favour of the early introduction of a cytotoxic or immunomodulating drug in addition to corticoster...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.7.1265

    authors: Fam AG

    更新日期:2001-07-01 00:00:00

  • Current Role of Dacomitinib in Head and Neck Cancer.

    abstract:INTRODUCTION:Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a dismal prognosis. With the emergence of monoclonal antibodies and tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR), several drugs were developed and tested in HNSCC. To date, the monoclonal...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2016.1177022

    authors: Elicin O,Ozsahin M

    更新日期:2016-06-01 00:00:00

  • The treatment of urinary tract infections and use of ciprofloxacin extended release.

    abstract::Urinary tract infections (UTIs) are one of the most common reasons people seek medical attention. There are > 50% of women who will have at least one UTI during their lifetime and most of these will require a physician visit and antibiotic treatment. The high prevalence continues to the in-patient setting where genito...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.5.519

    authors: Hickerson AD,Carson CC

    更新日期:2006-05-01 00:00:00

  • Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.

    abstract::The tremendous increase in the global prevalence of Type 2 diabetes (T2D) and its conglomeration of metabolic disorders has dramatically intensified the search for innovative therapies to fight this emerging epidemic. Over the last decade, the family of nuclear receptors, especially the peroxisome proliferator-activat...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.7.763

    authors: Savkur RS,Miller AR

    更新日期:2006-07-01 00:00:00

  • Tetomilast: new promise for phosphodiesterase-4 inhibitors?

    abstract:INTRODUCTION:Tetomilast is a novel thiazole phosphodiesterase-4 (PDE-4) inhibitor, which may prove useful in both the treatment of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). Here, the authors review the pharmacology of the drug, and offer critical review of the available data for...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.732065

    authors: Bickston SJ,Snider KR,Kappus MR

    更新日期:2012-12-01 00:00:00

  • Prostaglandin D2 receptor antagonists in early development as potential therapeutic options for asthma.

    abstract:INTRODUCTION:Asthma is a chronic inflammatory disease characterized by bronchial hyper-reactivity. Although many currently available treatment regimens are effective, poor symptom control and refractory severe disease still represent major unmet needs. In the last years, numerous molecular therapeutic targets that inte...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2016.1212838

    authors: Santus P,Radovanovic D

    更新日期:2016-09-01 00:00:00

  • The therapeutic potential of cationic peptides.

    abstract::Novel classes of antibiotics that are useful against resistant bacteria are a major need in human medicine. Cationic antimicrobial peptides are utilised as nature's antibiotics, being produced constitutively or in response to infection in virtually every type of organism from plants and insects to man. Thus, these pep...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.2.167

    authors: Hancock RE

    更新日期:1998-02-01 00:00:00

  • The therapeutic potential of phytoestrogens.

    abstract::Phytoestrogens, such as the soya isoflavones genistein and daidzein, are currently being extensively investigated through both molecular, preclinical and clinical studies to determine their potential health benefits. Phytoestrogens may protect against chronic diseases such as hormone-dependent cancer (e.g., breast and...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.8.1829

    authors: Wiseman H

    更新日期:2000-08-01 00:00:00

  • Identification of heptapeptides interacting with IFN-α-sensitive CML cells.

    abstract:BACKGROUND:Interferon-alpha (IFN-α) is the traditional therapeutic agent for chronic myeloid leukemia (CML). The molecular mechanism of IFN-α efficacy in the treatment of CML is not fully clear. OBJECTIVES:To identify the peptides and/or proteins that bind to the proteins specifically expressed on the surface of IFN-α...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.2011.632407

    authors: Liu J,Chen HC,Rao ZZ,Khan MA,Wan XX,Xu AH,Zhang N,Zhang DZ

    更新日期:2011-12-01 00:00:00

  • Imatinib mesylate for the treatment of pulmonary arterial hypertension.

    abstract:INTRODUCTION:Despite recent advances, pulmonary arterial hypertension (PAH) remains a devastating disease which harbors a poor prognosis. Novel therapeutic approaches directly targeting pulmonary vascular remodeling are warranted. AREAS COVERED:This review delineates the current limitations in the management of PAH an...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.632408

    authors: ten Freyhaus H,Dumitrescu D,Berghausen E,Vantler M,Caglayan E,Rosenkranz S

    更新日期:2012-01-01 00:00:00

  • Ticagrelor for the treatment of peripheral arterial disease.

    abstract:INTRODUCTION:Peripheral arterial disease (PAD) is a manifestation, and marker of severity, of a generalized atherosclerotic process. Antiplatelet therapy is recommended to prevent cardiovascular events but much of the evidence to support this is drawn from studies on older drugs. AREAS COVERED:In this review, the auth...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.974803

    authors: Chong AY,So DY

    更新日期:2014-12-01 00:00:00

  • Investigational drugs for eating disorders.

    abstract::The eating disorders anorexia nervosa, bulimia nervosa and binge eating disorder are common, significant public health problems which are treated with nutritional, psychotherapeutic and pharmacological interventions. A number of drugs (mostly antidepressant drugs) are currently used in their treatment to some benefit,...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.3.491

    authors: Crow S,Brown E

    更新日期:2003-03-01 00:00:00

  • Sirukumab : a novel therapy for lupus nephritis?

    abstract:INTRODUCTION:Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatme...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.950837

    authors: Thanarajasingam U,Niewold TB

    更新日期:2014-10-01 00:00:00

  • Angiotensin II type 2 receptor agonists--where should they be applied?

    abstract::It is now widely accepted that the renin-angiotensin system (RAS) not only contributes to pathological mechanisms involved, e.g. in hypertension or hypertensive and diabetic end-organ damage, but also harbors a "protective arm" represented mainly by two receptors, the AT2 (angiotensin type 2) receptor and the Mas rece...

    journal_title:Expert opinion on investigational drugs

    pub_type: 评论,杂志文章

    doi:10.1517/13543784.2012.681046

    authors: Steckelings UM,Unger T

    更新日期:2012-06-01 00:00:00